Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Acadia Pharmaceuticals Inc

NASDAQ: ACAD · Life Sciences · 7 alerts · CIK 1070494

Share price
$18.67Close, Nov 16
Market cap
$3.23B
Shares outstanding
172.83MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Acadia Pharmaceuticals Inc filings on SEC EDGAR ↗

5:11 PM ET 8-K
Clinical Trial Data

Acadia Pharmaceuticals Clinical Trial Data

Acadia Pharmaceuticals announced Phase 3 enabling topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer’s disease psychosis (ADP). While the 60 mg dose narrowly missed the primary endpoint (p=0.0603), it showed nominal significance on a key secondary endpoint and a favorable safety profile, leading the company to continue its Phase 3 program with the 60 mg dose.

Earnings call
Sep 24, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.